Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension

Phase

2/3

Condition

Vascular Diseases

Chest Pain

Heart Failure

Treatment

Midodrine Oral Tablet

Clinical Study ID

NCT06405555

5784

Ages > 18
All Genders

Study Summary

The evidence-based pharmacologic treatments available for patients with heart failure with reduced ejection fraction (HFrEF) has been established over the last few decades of cardiovascular research. These treatments, termed Foundational Guideline-Directed-Medical Therapies (GDMT), prolong patient life, improve patient-reported symptoms, and reduce hospitalizations for heart failure. A direct effect of most medication classes encompassed within GDMT is the reduction in blood pressure due to their mechanisms of action. In addition, as patients with HFrEF become more advanced in their disease, a significant proportion develop hypotension related to pump failure and autonomic dysfunction, amongst other possible mechanisms. As a result, a significant proportion of HFrEF patients are not optimized on GDMT with hypotension as their limiting barrier that would otherwise have served to improve their heart function, heart failure symptoms, and mortality. Currently, there does not exist any evidence-based strategies to address the problem of hypotension in HFrEF patients who are not optimized on GDMT.

Midodrine is an alpha-adrenergic agonist (α1-AR) that exerts its effects on peripheral venous and arteriolar vasculature to increase blood pressure. This medication has been used off-label by some clinicians in the hypotensive HFrEF population to increase blood pressure and has been reported to have beneficial effects in improving GDMT utilization as well as increasing left ventricular ejection fraction (LVEF) in published case reports/case series. There does not exist any randomized prospective data on the use of midodrine in the hypotensive HFrEF population. The investigators' objective is to complete the first open-label, randomized control trial of midodrine in the hypotensive HFrEF population to demonstrate feasibility in performing a trial in this patient population and to show efficacy in increasing blood pressure without associated harm. The results of this trial will be used as the foundation and rationale for future studies assessing the impact of midodrine use on GDMT utilization as well as hard cardiovascular outcomes in the hypotensive HFrEF population, including hospitalizations for heart failure and mortality.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Adults >= 18 years of age.
LVEF <= 40 % within the last 3 months as determined by any one of: Transthoracicechocardiogram, transesophageal echocardiogram, cardiac magnetic resonance imaging,MUGA scan, angiogram with left ventriculogram.
AHA/ACC Stage B or C Heart Failure
Hospitalized patients in the ward setting OR in the cardiac intensive care unit (whoare >= 48 hours after their last dose of vasopressor or inotrope).
Seated upright or supine SBP <= 100 mmHg on two or more consecutive BP measurementsseparated by at least 8 hours

Exclusion

Exclusion Criteria:

Patient OR substitute decision-maker (SDM) unwilling or unable to provide informedconsent
Documented allergy or intolerance to midodrine
Treatment for active infection (either documented infection or empiric treatment) withantimicrobials at the time of recruitment.
Current use OR any use within the last 48 hours of an intravenous inotrope orvasopressor medication OR the need for IV inotrope or vasoproessor use to treathypotension
Patient within 72 hours of an acute coronary syndrome.
Heart transplant recipient.
Presence of temporary or durable mechanical circulatory support device.
Severe valvular disease expected to be intervened upon during the incidenthospitalization.
Hyperkalemia >= 5.5 mmol/L.
Baseline eGFR (as calculated by the CKD-EPI method) <= 20 mL/min/1.73 m2 as measuredwithin the last 3 months.
A treatable cause for hypotension, including but not limited to: hypovolemia (eg.Bleeding, overdiuresis, poor oral intake), obstructive shock, sepsis, adrenalinsufficiency.
Clinical diagnosis of ongoing cardiogenic shock, or diagnosed as defined in SHOCKtrial: sBP <= 90 mmHg with evidence of end-organ hypoperfusion (cool extremities,urine output < 30 mL/hr, HR > 60 bpm, or elevated lactate >=3.5 mmol/L), invasivehemodynamic measurements (if available) of CI <= 2.2 L/min/m2 and a pulmonarycapillary wedge pressure (PCWP) of >=15 mmHg.
Pregnant patient.
Anticipated patient discharge in less than two days from enrolment (ie. less than 6anticipated doses of midodrine, if randomized to treatment/intervention arm).
Acute brain pathology (including, but not limited to intracranial hemorrhage orhematoma) in which most-responsible clinician deems it unsafe to augment bloodpressure.
Untreated thyrotoxicosis
Acute or acute on chronic liver failure
Patient unable to take oral medications
Bradycardia with resting heart rate less than 50 beats per minute.
Patients on an equivalent dose of Lasix >= 80 mg IV BID

Study Design

Midodrine Oral Tablet

2/3

August 01, 2024

July 01, 2026

Study Description

This will be a pilot, open-label, randomized controlled trial with the intervention/treatment being midodrine in hospitalized patients with HFrEF. The comparator/control arm will be patients following standard of care, which is to undergo no further pharmacologic intervention directed at hypotension unless clinically indicated. Patients who meet inclusion criteria will be randomized (1:1) to either midodrine group or control group, which will occur at the time of recruitment. In the treatment group, patients will receive midodrine for a total planned duration of up to 5 days, or until hospital discharge, whichever comes first. The midodrine will initially be started at 2.5 mg po TID for 1 day, followed by 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, and 10 mg po TID x 2 days. Side effects reported by patients and any adverse drug events will be documented. At the end of the inpatient study period, continuation of midodrine off-label will be at the treating clinician's discretion in the treatment arm.

For patients discharged home less than 1 week from the exposure period, patients will be followed for 2 weeks with the Telehome monitoring program (THM), which is a virtual outpatient service intended to closely follow heart failure patients, to monitor blood pressure, heart rate, weight and adverse events or side effects. For patients discharged home between 1 to 2 weeks from the exposure period, they will be followed for 1 week with THM. For patients discharged after 2 or more weeks from the exposure period, no THM follow-up will occur. Frequency of THM follow-up, as well as inpatient monitoring parameters is as outlined in the "Data Capture" section.

Key clinical measurements will be obtained in both treatment and control arms including blood pressure measurements (every 6 hours while awake, with each measurement in the treatment arm consisting of BP measured 1 hour after the administration of midodrine dose and in the supine position. For patients in the control arm, a similar frequency of blood pressures will be obtained at pre-specified times), NT-proBNP at the time of recruitment (Day 0, prior to administration of midodrine in treatment arm) and after 5 days (ie. Sample obtained at time of last dose at Day 4 or at Day 5) or hospital discharge (whichever comes first). Safety outcomes will be monitored for and assessed. The study will be open-label and neither the patient nor the treating physicians will be blinded in this study.